T1	PROC 46 74	Evaluación de los resultados
T2	PROC 132 143	tratamiento
#1	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	DISO 186 205	esclerosis múltiple
#2	AnnotatorNotes T3	C0026769; Multiple Sclerosis; Disease or Syndrome
T4	PROC 210 256	estudio ambispectivo, exploratorio, en fase IV
T5	PROC 311 327	ensayos clínicos
#3	AnnotatorNotes T5	C0008976; Clinical Trials; Research Activity
T6	CHEM 1367 1377	Cladribine
#4	AnnotatorNotes T6	C0092801; cladribine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T7	DISO 383 402	ESCLEROSIS MULTIPLE
#5	AnnotatorNotes T7	C0026769; Multiple Sclerosis; Disease or Syndrome
T8	PROC 469 489	resonancia magnética
#6	AnnotatorNotes T8	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T9	PROC 511 524	aleatorizados
#7	AnnotatorNotes T9	C0034656; Randomization; Research Activity
T10	PROC 528 544	ensayos clínicos
#8	AnnotatorNotes T10	C0008976; Clinical Trials; Research Activity
T11	CHEM 614 624	Cladribine
#9	AnnotatorNotes T11	C0092801; cladribine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T12	PROC 627 634	placebo
#10	AnnotatorNotes T12	C0032042; Placebos; Therapeutic or Preventive Procedure
T13	PROC 680 694	ensayo clínico
#11	AnnotatorNotes T13	C0008976; Clinical Trials; Research Activity
T14	PROC 761 768	placebo
#12	AnnotatorNotes T14	C0032042; Placebos; Therapeutic or Preventive Procedure
T15	PROC 802 826	consentimiento informado
#13	AnnotatorNotes T15	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T16	PROC 926 935	protocolo
#14	AnnotatorNotes T16	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T17	DISO 1033 1043	enfermedad
#15	AnnotatorNotes T17	C0012634; Disease; Disease or Syndrome
T18	PROC 1247 1257	evaluación
#16	AnnotatorNotes T18	C1261322; Evaluation procedure; Health Care Activity
T19	PROC 1271 1274	MRI
#17	AnnotatorNotes T19	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T20	PROC 1496 1510	ensayo clínico
#18	AnnotatorNotes T20	C0008976; Clinical Trials; Research Activity
T21	PROC 1513 1534	estudio observacional
#19	AnnotatorNotes T21	C1518527; Observational Study; Research Activity
T22	CHEM 1563 1573	Cladribine
#20	AnnotatorNotes T22	C0092801; cladribine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T23	CHEM 167 177	cladribina
#21	AnnotatorNotes T23	C0092801; cladribine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T24	DISO 508 510	EM
#22	AnnotatorNotes T24	C0026769; Multiple Sclerosis; Disease or Syndrome
T25	CHEM 740 750	Cladribine
#23	AnnotatorNotes T25	C0092801; cladribine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T26	DISO 1072 1074	EM
#24	AnnotatorNotes T26	C0026769; Multiple Sclerosis; Disease or Syndrome
T27	Date 13 17	2019
T28	Date 75 88	a largo plazo
T29	Form 152 163	comprimidos
#25	AnnotatorNotes T29	C0039225; Tablet Dosage Form; Biomedical or Dental Material
T30	LIVB 260 269	pacientes
#26	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	LIVB 494 503	Pacientes
#27	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group
T32	Form 602 610	tabletas
#28	AnnotatorNotes T32	C0039225; Tablet Dosage Form; Functional Concept
T33	LIVB 639 648	Pacientes
#29	AnnotatorNotes T33	C0030705; Patients; Patient or Disabled Group
T34	LIVB 778 787	pacientes
#30	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T37	Neg_cue 1062 1064	no
T38	LIVB 1345 1353	paciente
#31	AnnotatorNotes T38	C0030705; Patients; Patient or Disabled Group
T39	LIVB 1465 1474	pacientes
#32	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T40	Neg_cue 1540 1542	no
T41	Form 1551 1559	tabletas
#33	AnnotatorNotes T41	C0039225; Tablet Dosage Form; Functional Concept
T42	LIVB 1290 1303	Participantes
#34	AnnotatorNotes T42	C4554048; Study Participant; Population Group
T36	PHYS 1326 1337	embarazadas
#35	AnnotatorNotes T36	C0032961; Pregnancy; Organism Function
T35	PROC 661 673	aleatorizado
#36	AnnotatorNotes T35	C0034656; Randomization; Research Activity
A2	Assertion T26 Negated
A3	Assertion T41 Negated
A4	Assertion T22 Negated
#37	AnnotatorNotes T1	C1285276; Evaluation of test results; Diagnostic Procedure
#38	AnnotatorNotes T28	C0443252; Long-term; Temporal Concept
T43	Neg_cue 1044 1046	no
T44	Quantifier_or_Qualifier 1047 1057	controlada
A1	Assertion T44 Negated
T45	Spec_cue 1193 1199	podría
T46	CONC 1200 1210	interferir
A5	Assertion T46 Speculated
#39	AnnotatorNotes T46	C0521102; Interferes with; Functional Concept
R1	Overlap Arg1:T1 Arg2:T28	
T47	Observation 113 119	efecto
#40	AnnotatorNotes T47	C1518681; Outcome of Therapy; Finding (?)
R2	After Arg1:T47 Arg2:T2	
R3	Used_for Arg1:T23 Arg2:T2	
R4	Has_Drug_Form Arg1:T23 Arg2:T29	
R5	Experiences Arg1:T30 Arg2:T3	
R6	Experiences Arg1:T30 Arg2:T47	
R7	Experiences Arg1:T30 Arg2:T2	
T48	Observation 278 289;304 306;311 327	participado en ensayos clínicos
A6	Status T48 History_of
#41	AnnotatorNotes T48	C1278516; Patient participation status; Finding (?)
R9	Experiences Arg1:T31 Arg2:T24	
R10	Has_Drug_Form Arg1:T11 Arg2:T32	
R11	Experiences Arg1:T31 Arg2:T11	
R12	Experiences Arg1:T31 Arg2:T12	
R13	Experiences Arg1:T33 Arg2:T25	
R14	Experiences Arg1:T33 Arg2:T14	
R15	Before Arg1:T9 Arg2:T11	
R16	Before Arg1:T9 Arg2:T12	
R17	Before Arg1:T35 Arg2:T25	
R18	Before Arg1:T35 Arg2:T14	
T49	Quantifier_or_Qualifier 722 731	≥ 1 ciclo
R19	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T49	
R20	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T49	
R22	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T44	
R23	Negation Arg1:T43 Arg2:T44	
R24	Negation Arg1:T37 Arg2:T26	
T51	Observation 1109 1115	riesgo
T52	Observation 1159 1186	participación en el estudio
A7	Assertion T52 Contraindicated
R25	Before Arg1:T17 Arg2:T52	
R26	Speculation Arg1:T45 Arg2:T46	
R28	Experiences Arg1:T42 Arg2:T36	
R29	Experiences Arg1:T38 Arg2:T6	
T53	CONC 1431 1453	inicio de este estudio
#43	AnnotatorNotes T53	C4684789; Study Start; Temporal Concept
R30	Overlap Arg1:T6 Arg2:T53	
T54	Observation 1391 1412	parte de otro estudio
R33	Overlap Arg1:T54 Arg2:T53	
T55	Observation 1479 1534	participan en un ensayo clínico o estudio observacional
#44	AnnotatorNotes T55	C1278516; Patient participation status; Finding (?)
R36	Has_Drug_Form Arg1:T22 Arg2:T41	
R37	Negation Arg1:T40 Arg2:T41	
R38	Negation Arg1:T40 Arg2:T22	
R40	Experiences Arg1:T39 Arg2:T22	
R41	Before Arg1:T22 Arg2:T53	
T56	Quantifier_or_Qualifier 584 593	≥ 1 ciclo
R42	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T56	
R43	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T56	
T57	CHEM 735 738	IMP
#45	AnnotatorNotes T57	C0013230; Investigational New Drugs; Pharmacologic Substance (?) ['investigational medicinal product']
R44	Has_Quantifier_or_Qualifier Arg1:T57 Arg2:T49	
R45	Before Arg1:T35 Arg2:T57	
R46	Experiences Arg1:T33 Arg2:T57	
T58	CHEM 597 600	IMP
#46	AnnotatorNotes T58	C0013230; Investigational New Drugs; Pharmacologic Substance (?) ['investigational medicinal product']
R47	Has_Quantifier_or_Qualifier Arg1:T58 Arg2:T56	
R48	Has_Drug_Form Arg1:T58 Arg2:T32	
R49	Before Arg1:T9 Arg2:T58	
R50	Experiences Arg1:T31 Arg2:T58	
#42	AnnotatorNotes T51	C0559571; At risk; Finding
#47	AnnotatorNotes T52	C1278516; Patient participation status; Finding
R21	Causes Arg1:T23 Arg2:T47	
R8	Experiences Arg1:T39 Arg2:T6	
R27	Experiences Arg1:T38 Arg2:T22	
A8	Experiencer T30 Patient
A9	Experiencer T31 Patient
A10	Experiencer T33 Patient
A11	Experiencer T34 Patient
A12	Experiencer T42 Patient
A13	Experiencer T38 Patient
A14	Experiencer T39 Patient
